Search

Your search keyword '"Ferric Compounds pharmacokinetics"' showing total 507 results

Search Constraints

Start Over You searched for: Descriptor "Ferric Compounds pharmacokinetics" Remove constraint Descriptor: "Ferric Compounds pharmacokinetics"
507 results on '"Ferric Compounds pharmacokinetics"'

Search Results

101. Iron oxide nanoparticles for neuronal cell applications: uptake study and magnetic manipulations.

102. Magneto acoustic tomography with short pulsed magnetic field for in-vivo imaging of magnetic iron oxide nanoparticles.

103. Detection of experimental myocardium infarction in rats by MRI using heat shock protein 70 conjugated superparamagnetic iron oxide nanoparticle.

104. Probing suitable therapeutic nanoparticles for controlled drug delivery and diagnostic reproductive health biomarker development.

105. Hybrid Iron Oxide-Graphene Oxide-Polysaccharides Microcapsule: A Micro-Matryoshka for On-Demand Drug Release and Antitumor Therapy In Vivo.

106. Particle Size, Surface Area, and Amorphous Content as Predictors of Solubility and Bioavailability for Five Commercial Sources of Ferric Orthophosphate in Ready-To-Eat Cereal.

107. Pharmacokinetics and bio-distribution of novel super paramagnetic iron oxide nanoparticles (SPIONs) in the anaesthetized pig.

108. Synthesis and Testing of Modular Dual-Modality Nanoparticles for Magnetic Resonance and Multispectral Photoacoustic Imaging.

109. Liver Function Assessment Using Parenchyma-Specific Contrast-Enhanced Ultrasonography.

110. Disturbance of ion environment and immune regulation following biodistribution of magnetic iron oxide nanoparticles injected intravenously.

111. Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors.

112. Synthesis and Evaluation of Thermo-Sensitive, Magnetic Fluorescent Nanocomposite as Trifunctional Drug Delivery Carrier.

113. Effects of Iron-Oxide Nanoparticle Surface Chemistry on Uptake Kinetics and Cytotoxicity in CHO-K1 Cells.

114. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles.

115. Chemical sporulation and germination: cytoprotective nanocoating of individual mammalian cells with a degradable tannic acid-FeIII complex.

116. Study on the interaction of Fe(III) complex of BODIPY appended di(picolyl)amine with water and HeLa cells.

117. Iron bioavailability in 8-24-month-old Thai children from a micronutrient-fortified quick-cooking rice containing ferric ammonium citrate or a mixture of ferrous sulphate and ferric sodium ethylenediaminetetraacetic acid.

118. Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging.

119. Chronic pulmonary accumulation of iron oxide nanoparticles induced Th1-type immune response stimulating the function of antigen-presenting cells.

120. Self-assembled microbubbles as contrast agents for ultrasound/magnetic resonance dual-modality imaging.

121. The One Year Fate of Iron Oxide Coated Gold Nanoparticles in Mice.

122. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.

123. Targeted Mesoporous Iron Oxide Nanoparticles-Encapsulated Perfluorohexane and a Hydrophobic Drug for Deep Tumor Penetration and Therapy.

124. Oral iron absorption test should not be performed with iron drops containing ferric iron.

125. Rapid Nucleation of Iron Oxide Nanoclusters in Aqueous Solution by Plasma Electrochemistry.

126. Synthesis of acid-stabilized iron oxide nanoparticles and comparison for targeting atherosclerotic plaques: evaluation by MRI, quantitative MPS, and TEM alternative to ambiguous Prussian blue iron staining.

127. The toxicity and distribution of iron oxide-zinc oxide core-shell nanoparticles in C57BL/6 mice after repeated subcutaneous administration.

128. Comparative toxicity of silicon dioxide, silver and iron oxide nanoparticles after repeated oral administration to rats.

129. 99mTc-Labeled Iron Oxide Nanoparticles for Dual-Contrast (T1/T2) Magnetic Resonance and Dual-Modality Imaging of Tumor Angiogenesis.

130. Safety assessment of chronic oral exposure to iron oxide nanoparticles.

131. Smart MoS2/Fe3O4 Nanotheranostic for Magnetically Targeted Photothermal Therapy Guided by Magnetic Resonance/Photoacoustic Imaging.

132. Functionalized magnetic iron oxide/alginate core-shell nanoparticles for targeting hyperthermia.

133. Biocompatible Low-Retention Superparamagnetic Iron Oxide Nanoclusters as Contrast Agents for Magnetic Resonance Imaging of Liver Tumor.

134. Alternating magnetic field-induced hyperthermia increases iron oxide nanoparticle cell association/uptake and flux in blood-brain barrier models.

135. In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: toward earlier diagnosis of Alzheimer's disease by molecular imaging.

136. Dextrin-based nanomagnetogel: in vivo biodistribution and stability.

137. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.

138. Accumulation and elimination of iron oxide nanomaterials in zebrafish (Danio rerio) upon chronic aqueous exposure.

139. Dietary iron depletion at weaning imprints low microbiome diversity and this is not recovered with oral Nano Fe(III).

140. Synthesis, characterization and theranostic evaluation of Indium-111 labeled multifunctional superparamagnetic iron oxide nanoparticles.

141. Reference values for oral iron absorption of bivalent iron in healthy volunteers.

142. Nanothermodynamics mediates drug delivery.

143. Hyperenhanced Rim Surrounding Liver Metastatic Tumors in the Postvascular Phase of Sonazoid-Enhanced Ultrasonography: A Histological Indication of the Presence of Kupffer Cells.

144. Integrity of (111)In-radiolabeled superparamagnetic iron oxide nanoparticles in the mouse.

145. Surface charge and dosage dependent potential developmental toxicity and biodistribution of iron oxide nanoparticles in pregnant CD-1 mice.

146. Bioaccessibility of arsenic in mining-impacted circumneutral river floodplain soils.

147. Iron uptake and ferrokinetics in healthy male subjects of an iron-based oral phosphate binder (SBR759) labeled with the stable isotope (58)Fe.

148. Synthesis, characterization, and cellular uptake of magnetic nanocarriers for cancer drug delivery.

149. Structural differences of prebiotic oligosaccharides influence their capability to enhance iron absorption in deficient rats.

150. X-ray and electron microscopy studies on the biodistribution and biomodification of iron oxide nanoparticles in Daphnia magna.

Catalog

Books, media, physical & digital resources